ARTICLE

Volume 10,Issue 7

All Issues
Submit to JCNR
Cite this article
1
Citations
2
Views
7 January 2025
Evaluation Study on the Effect of Leuprolide Acetate Extended-Release Microspheres for Injection in Pediatric Precocious Puberty
Huihui Ren ,  Xiaolong Song
Show Less
1 Department of Clinical Laboratory, Tibet Autonomous Region Women and Children's Hospital, Lhasa, 851414, China,
2 Radioimmunoassay Center, Department of Clinical Laboratory, Shaanxi Provincial People’s Hospital, Xi’an 710068, China,
JCNR 2024 , 8(12), 331–336; https://doi.org/10.26689/jcnr.v8i12.9304
© 2024 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
HTML
Abstract

Objective: This study aimed to evaluate the therapeutic effects of leuprolide acetate extended-release microspheres for injection in children with pediatric precocious puberty. Methods: A total of 110 cases of pediatric precocious puberty admitted between January 2019 and December 2021 were selected and randomized into two groups using a random number table, with 55 cases in the control group and 55 cases in the experimental group. The control group received conventional treatment, while the experimental group was treated with leuprolide acetate extended-release microspheres for injection. The therapeutic effects were observed, and changes in sex hormone levels, ovarian volume, growth indices, and the incidence of adverse reactions were statistically compared between the groups. Results: The experimental group demonstrated superior outcomes in terms of sex hormone levels, ovarian volume, and growth indices compared to the control group. Additionally, the incidence of adverse reactions in the experimental group was significantly lower (P < 0.05). Conclusion: The application of leuprolide acetate extended-release microspheres for the treatment of pediatric precocious puberty is associated with improved therapeutic effects and higher safety.

References
Endocrine Genetic Metabolism Group of the Pediatrics Branch of the Chinese Medical Association, Editorial Board of the Chinese Journal of Pediatrics, 2015, Consensus on the Diagnosis and Treatment of Central Precocious Puberty (2015). Chinese Journal of Pediatrics, 53(6): 412–418.
Tirumuru SS, Arya P, Latthe P, 2012, Understanding Precocious Puberty in Girls. Obstetrician Gynaecologist, 14: 121–129. https://doi.org/10.1111/j.1744-4667.2012.00094.x
Yang M, Tang S, Xin Y, 2020, A Case Report of a Patient with Precocious Puberty and Karyotype 45, X/46, XX/47, XXX Turner Syndrome. Chinese Journal of Evidence-Based Pediatrics, 15(6): 463–466.
Wang M, Gao Y, Li X, et al., 2019, Effectiveness and Safety of GnRHa Combined with rhGH in Improving Predicted Adult Height in Children with Idiopathic Central Precocious Puberty at Different Ages. China Maternal and Child Health, 34(16): 3703–3704.
Xu L, Hong Q, Fang Y, 2022, Clinical Efficacy of Treprostinil in Girls with Idiopathic Central Precocious Puberty and Effect on Bone Age. International Journal of Medicine and Health, 28(6): 829–832.
Ma X, Ni J, Yang L, et al., 2020, Long-Term Effects of GnRHa Treatment on Children with Idiopathic Central Precocious Puberty and Rapidly Progressive Precocious Puberty. Chinese Journal of Endocrinology and Metabolism, 36(1): 58–62.
Chen J, Lin Y, Zhou Y, et al., 2020, Analysis of Clinical Regression and Risk Factors of Central Precocious Puberty in Girls with Premature Breast Development. Zhejiang Medicine, 42(8): 811–814.
Chu Z, Jiang H, Wu Q, 2021, Meta-analysis of Gonadotropin-Releasing Hormone Analog Treatment on the Improvement of Adult Lifelong Height in Children with Central Precocious Puberty and Rapidly Progressive Puberty. Chinese Journal of Contemporary Pediatrics, 11: 1161–1168.
Guaraldi F, Beccuti G, Gori D, et al., 2016, Management of Endocrine Disease: Long-Term Outcomes of the Treatment of Central Precocious Puberty. Eur J Endocrinol, 174(3): R79–R87. https://doi.org/10.1530/EJE-15-0590
Liang Y, Wei H, Li J, et al., 2015, Effect of GnRHa 3.75 mg Subcutaneously Every 6 Weeks on Adult Height in Girls with Idiopathic Central Precocious Puberty. J Pediatr Endocrinol Metab, 28(7–8): 839–846. https://doi.org/10.1515/jpem-2014-0305
Wang XP, Xu X, Jiang L, et al., 2020, Efficacy of Recombinant Human Growth Hormone Combined with Leuprolide in the Treatment of Girls with Idiopathic Central Precocious Puberty. Journal of Pediatric Pharmacy, 26(7): 17–20.
Feng Y, 2020, Evaluation of the Efficacy of Leuprolide Extended-Release Microspheres in Children with Central Precocious Puberty. Wisdom Health, 6(24): 50–51 + 54.
Yu Y, Hou W, Ding H, et al., 2021, Observations on the Efficacy of Dangdaji Yuanyuan Capsule Combined with Trenbolone Acetate in the Treatment of Idiopathic Pivotal Precocious Puberty in Female Children. Journal of Xinxiang Medical College, 38(11): 1048–1052.
Luo X, Liang Y, Hou L, et al., 2021, Long-Term Efficacy and Safety of Gonadotropin-Releasing Hormone Analog Treatment in Children with Idiopathic Central Precocious Puberty: A Systematic Review and Meta-Analysis. Clin Endocrinol (Oxf), 94(5): 786–796. https://doi.org/10.1111/cen.14410
Fu J, Zhang J, Chen R, et al., 2020, Long-Term Outcomes of Treatments for Central Precocious Puberty or Early and Fast Puberty in Chinese Girls. J Clin Endocrinol Metab, 105(3): dgz027. https://doi.org/10.1210/clinem/dgz027
Ma X, Ni J, Yang L, et al., 2020, Long-Term Effects of GnRHa Treatment on Children with Idiopathic Central Precocious Puberty and Rapidly Progressive Precocious Puberty. Chinese Journal of Endocrinology and Metabolism, 36(1): 58–62.
Share
Back to top
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept